Our Story
Our Pipeline
Press
Career
Contact
CN
Stay informed about our latest updates.
Press releases
April 12, 2023
Overland ADCT BioPharma Announces Pivotal Phase 2 Clinical Trial in China Evaluating ZYNLONTA® for DLBCL Achieves Primary Objective
November 02, 2022
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
July 11, 2022
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
March 01, 2022
Overland Pharmaceuticals Appoints Dr. Xun Liu as Chief Technology Officer
January 18, 2022
Overland Pharmaceuticals Appoints Ed Zhang as Chief Executive Officer and Welcomes Industry Leaders John Maraganore and Peter Ho as Strategic Advisors
September 29, 2021
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
August 02, 2021
Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as Chief Development Officer
June 21, 2021
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
April 06, 2021
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
December 15, 2020
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
December 14, 2020
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
December 09, 2020
Overland Pharmaceuticals Debuts as Premier Biopharmaceutical Company to Bring Innovative Medicines to Asia and Worldwide
Scroll to top